Skip to content
sellWeak cluster of 310b5-1 plan

Stephen Michael Kelsey sold $1.2M of RVMD

See Remarks at Revolution Medicines, Inc.. 25,000 shares at an average of $48.54, traded Oct 13, 2025, filed Oct 15, 2025.

Warning score
20
Value
$1.2M
25,000 shares
Holdings after
284,047
-8% from before
From 52-week low
+57%
low $31.13, close $48.75
From 52-week high
-20%
high $60.60, as of Oct 13, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $1.2M at market
    +25
  • Share of holdings sold
    Sold 8.1% of holdings
    0
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

RVMDOct 9, 2026 · close 189.76
Since filing Oct 15, 2025: +282.9%SPY +18.3% · excess +264.6%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001610717-25-000361, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 13, 2025MOption exercise
Common Stock10b5-1
+25,000$4.73$118k309,047Oct 15, 2025
Oct 13, 2025SOpen-market sale
Common Stock10b5-1
-25,000$48.54$1.2M284,047Oct 15, 2025
Oct 13, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-25,000$0.00$05,055Oct 15, 2025

Related signals

Other insiders at Revolution Medicines, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
25Weak
RVMDsell 810b5-1
Revolution Medicines, Inc.
Alan B. Sandler
Chief Development Officer
$1.3M
6,309 shares
-11%
21Weak
RVMDsell 810b5-1
Revolution Medicines, Inc.
Jeff Cislini
SVP & General Counsel
$159k
765 shares
-1%
16Weak
RVMDsell 810b5-1
Revolution Medicines, Inc.
Anthony Mancini
See Remarks
$743k
3,708 shares
-9%
40Moderate
RVMDsell 910b5-1
Revolution Medicines, Inc.
Elizabeth M Anderson
director
$2.0M
10,143 shares
-70%
25Weak
RVMDsell 910b5-1
Revolution Medicines, Inc.
Anthony Mancini
See Remarks
$347k
1,764 shares
-4%
39Weak
RVMDsell 910b5-1
Revolution Medicines, Inc.
Jack Anders
Chief Financial Officer
$808k
4,053 shares
-3%
30Weak
RVMDsell 910b5-1
Revolution Medicines, Inc.
Jeff Cislini
SVP & General Counsel
$671k
3,366 shares
-6%
35Weak
RVMDsell 910b5-1
Revolution Medicines, Inc.
Mark A Goldsmith
See Remarks
$2.8M
13,988 shares
-5%
40Moderate
RVMDsell 910b5-1
Revolution Medicines, Inc.
Margaret A Horn
Chief Operating Officer
$990k
4,967 shares
-3%
35Weak
RVMDsell 910b5-1
Revolution Medicines, Inc.
Stephen Michael Kelsey
See Remarks
$1.1M
5,569 shares
-2%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Stephen Michael Kelsey sold $1.2M of RVMD | InsiderTell